CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
dexamethasone intraocular suspension, 9% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04184999
NCT04184999Phase 4Completed
CompareCT.gov

Evaluation of Intraoperative Use of Dexycu on the Signs and Symptoms of Dry Eye

SR Cornea Consultants·interventional·Posted Dec 4, 2019·Updated Nov 22, 2023

In Brief

A Phase 4 clinical trial evaluating dexamethasone intraocular suspension, 9% and Prednisolone Acetate 1% Oph Susp for Dry Eye Syndromes. Completed, enrolled 40 participants across 1 site.

Detailed Summary

To compare the signs and symptoms of dry eye after cataract surgery between subjects randomized to receive intraoperative dexamethasone in addition to the use of a standard topical post-op treatment regimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedDec 4, 2019
Enrollment StartAug 10, 2019
Primary CompletionDec 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.6 years ago

Interventions

dexamethasone intraocular suspension, 9%drug

single dose intracameral corticosteroid

Prednisolone Acetate 1% Oph Suspdrug

topical ophthalmic steroid drop